Hergen Spits, University of Amsterdam, The Netherlands
Rick Maizels

Hergen Spits graduated in 1984 from the University of Amsterdam. After a two-year post-doctoral period at the Netherlands Cancer Institute (NKI) in Amsterdam, he joined Schering Plough (SP) in 1985. From 1988 through 1992, Spits worked at the DNAX Research Institute in Palo Alto, CA, USA. In 1993 he returned to the NKI to assume the position of senior scientist in the division of Immunology. From 2000 through 2002 he was head of this division. In October 2002 he became Professor of Cell Biology at the Academic Medical Center, University of Amsterdam. In 2004 dr Spits co-founded AIMM Therapeutics to commercialize a technology, he developed to immortalize human B cells. In 2006 he joined Genentech Inc. in South San Francisco, CA, USA. From 2006 until 2008 Spits was responsible for the drugs discovery efforts in the autoimmune disease program of Genentech and in 2008 he became head of the Cancer Immunotherapy Program. In July 2009 Spits returned to the AMC in Amsterdam where he is currently professor in cell biology. Spits has a long standing interest in the biology of human lymphocytes. He was one of the first to describe human Th1 cell subsets and recently he discovered Th22 cells. His work now focuses on the biology of human ILC subsets

« Go Back

Supporting Publications
Cell Host & Microbe
Trends in Immunology
Trends in Microbiology
Trends in Parasitology
In partnership with
Premier Sponsor
R&D systems a bio-techne brand
  • Invivogen
  • biolegend
  • BD